Crystal Pharmatech
Pharmaceutical Manufacturing • 
Cranbury, New Jersey, United States • 51-100 Employees
Company overview
| Headquarters | 3000 Eastpark Blvd, Suite 500B, Cranbury, New Jersey 08512, US |
| Phone number | +16096048303 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Formulation, Polymorph Screening, Formulation Development, Gmp Manufacturing, Preformulation, Amorphous Solid Dispersion, Api Characterization, Api Crystallization, Api Process Optimization, Chiral Resolution, Cocrystal Screening, Crystallization Development And Optimization, Formulation Characterization, Salt Screening, Clinical And Commercial Manufacturing |
| Founded | 2010 |
| Employees | 51-100 |
| Socials |
Key Contacts at Crystal Pharmatech
Yan Li
Senior Director Business Development
Michael Ragno
Director Of Growth & Partnerships
Bethlehem Negash
Director Of Business Development
Mandy Zhu
Associate Director-Project Management And Business Operation
Xiaoxia Chen
Chief Technology Officer
Yanfeng Zhang
Chief Scientific Officer, Co-Founder
Xiaoling Zhou
Head Of Ap Bd At Crystal Pharmatech. Director Of Business Development
墨翰 张
Ceo Secretary
Xia L.
Director
燕 周
Director
Crystal Pharmatech Email Formats
Crystal Pharmatech uses 3 email formats. The most common is {first name}_{last name} (e.g., john_doe@crystalpharmatech.com), used 64.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}_{last name} | john_doe@crystalpharmatech.com | 64.5% |
{first initial}_{last name} | j_doe@crystalpharmatech.com | 35.5% |
About Crystal Pharmatech
Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing four strategically located R&D centers in New Jersey (USA), California (USA), Toronto (Canada), and Suzhou (China), we are powered by a skilled team of around 300 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.
Crystal Pharmatech revenue & valuation
| Annual revenue | $37,500,000 |
| Revenue per employee | $481,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $120,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Crystal Pharmatech has 36 employees across 6 departments.
Departments
Number of employees
Funding Data
Crystal Pharmatech has never raised funding before.
South Africa
Germany
Spain
Canada
United KingdomFrequently asked questions
4.8
40,000 users
